Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck astraZeneca (Lynparza & Koselugo Oncology Alliance) — Net R&D cost-sharing expense ($M) ($M)
Form 10-Q / 10-K Note 3/4 Collaborative Arrangements
Latest, FY2025
36
Period ended Dec 31, 2025
Change on a year earlier
-53.2%
77 in FY2024
History
8 years
Since FY2017
Sources
6
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | AstraZeneca (Lynparza & Koselugo Oncology Alliance) — Net R&D cost-sharing expense ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 36 | -53.2% | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 77 | -2.5% | Form 10-K (filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 79 | -25.5% | Form 10-K (filed 2026-02-24) ↗ |
| FY2022 | Dec 31, 2022 | 106 | -11.7% | Form 10-K (filed 2025-02-25) ↗ |
| FY2021 | Dec 31, 2021 | 120 | -9.8% | Form 10-K (filed 2024-02-26) ↗ |
| FY2020 | Dec 31, 2020 | 133 | -20.8% | Form 10-K (filed 2023-02-24) ↗ |
| FY2019 | Dec 31, 2019 | 168 | – | Form 10-K (filed 2022-02-25) ↗ |
| FY2017 | Dec 31, 2017 | 2,350 | – | Form 10-K (filed 2020-02-26) ↗ |
Cite this data
StockData. (2026). Merck AstraZeneca (Lynparza & Koselugo Oncology Alliance) — Net R&D cost-sharing expense ($M) ($M), annual FY2017–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/collab_astrazeneca_rd
See every metric in the Merck KPI table. Data updated Oct 26, 2026.